BioMarin Pharma (BMRN) Tops Q1 EPS by 20c

BioMarin Pharma (NASDAQ: BMRN) reported Q1 GAAP EPS of ($0.09), $0.20 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $304 million versus the consensus estimate of $288.98 million.

Non-GAAP income for the first quarter ended March 31, 2017 was $35 million, compared to non-GAAP loss of $29 million for the quarter ended March 31, 2016.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $59 at H.C. Wainwright
• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance